ESMO 2022: PRESTO - A Phase 3 Androgen Annihilation in Biochemically Relapsed Prostate Cancer

By The Uromigos - Last Updated: September 11, 2022

Rahul Aggarwal describes the results of the randomized phase 3 PRESTO study that examined the effects of androgen suppressants on biochemically relapsed prostate cancer.

Post Tags:Uromigos-ESMO

Related Podcasts

Episode 280: IKCS 2023 Overview
Uromigos-IKCS 2023
Episode 279: Management of IO-resistant RCC at #UromigosLive 2023
Uromigos Live 2023-Renal Cell Carcinoma
Episode 278: The Current and Future Status of Radioligand Therapy at #UromigosLive 2023
Uromigos Live 2023-Prostate Cancer
Episode 277: NMIBC Discussion at #UromigosLive 2023
Uromigos Live 2023-Bladder Cancer
Episode 276: ESMO 2023 Highlights
Uromigos-ESMO
Advertisement
Advertisement

  • 630 Madison Ave.

    Manalapan, NJ 07726

    • About

    About Us

    Contributors and Partners

    Editorial Policy

    Advertising

    Connect

    eNewsletters

    Calendar

    Contact Us

    Contribute

    Our Network

    MashupMD

    Cancer Nursing Today

    Urban Health Today

    Blood Cancers Today

    DocWire News

    © 2023 Mashup Media, LLC. All rights reserved.

    Terms of Use | Privacy Policy